FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				1									1					
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MARCUS JOEL S					Intra-Cellular Therapies, Inc. [ ITCI ]								X		Director		10% Owner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 12/04/2015										Officer (give title below)		Other below	(specify
C/O ALEXANDRIA REAL ESTATE				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	dividual o	Il or Joint/Group Filing (Check Applicable			
EQUITIES,INC. 385 EAST COLORADO BOULEVARD, SUITE 299													Line)	Form filed by One Reporting Person				
													Λ		Form filed by More than One Reporting			
(Street) PASADENA CA 91101														Pers	on			
(City)	(51:		Zip)															
4			e I - Non-Deriv				Acqu	uire	d, D									
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Ye	ar) E	2A. Deemed Execution Date, r) if any (Month/Day/Year)		Transaction Code (Instr.			4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			r and	Securit Benefic	5. Amount of Securities Beneficially Owned		n: Direct	7. Nature of Indirect Beneficial Ownership	
								Code V		Amount	(A) or (D)	Price		Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
Common	Stock		12/04/201:	5			S	S		30,000(1)	D	\$55.9	96 <sup>(2)</sup>	1,25	3,856			See Footnote <sup>(1)</sup>
Common	Stock		12/07/201	5			S	5		15,075(1)	D	\$52.	.15	1,23	8,781			See Footnote <sup>(1)</sup>
Common Stock		12/07/201:	5			S	5		24,925(1)	D	\$53.	3.78 1,2		3,856			See Footnote <sup>(1)</sup>	
Common Stock			12/08/201:	5			S	S		22,700(1)	D	\$54	\$54.8 1		1,191,156			See Footnote <sup>(1)</sup>
Common Stock														18	,722		D	
Common Stock														15	,742		I	Held by the Joel S. Marcus and Barbara A. Marcus Family Trust
		Та	ble II - Derivat							posed of, convertib				Owned				
1. Title of 2. 3. Transaction Derivative Conversion Date Executiv Security or Exercise (Month/Day/Year) if any			3A. Deemed Execution Date,	4. Trans Code	saction (Instr.	5. Num of Derivat Securit Acquire (A) or Dispos of (D) (Instr. 3 and 5)	ber (ive (ies	Expiration (Month/Day		ercisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. of De Se (Ir	rivative Scurity Estr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A) (I	Date D) Exercisa		isabl	Expiration e Date	Title	or Number of Shares	er						

## **Explanation of Responses:**

<sup>1.</sup> Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$55.95 to \$56.00, inclusive. The reporting person undertakes to provide to Intra-Cellular Therapies, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4.

## Remarks:

/s/ Lawrence J. Hineline. Attorney-in-fact 12/08/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.